摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2,4-二氟苯氧基)乙酸 | 399-44-0

中文名称
(2,4-二氟苯氧基)乙酸
中文别名
(2,4-二氟-苯氧基)-乙酸
英文名称
2-(2,4-difluorophenoxy)acetic acid
英文别名
(2,4-difluoro-phenoxy)-acetic acid;(2,4-Difluor-phenoxy)-essigsaeure;[(2,4-difluorophenyl)oxy]acetic acid;2,4-difluorophenoxyacetic acid;2,4-Difluor-phenoxy-essigsaeure;(2,4-Difluorophenoxy)acetic acid
(2,4-二氟苯氧基)乙酸化学式
CAS
399-44-0
化学式
C8H6F2O3
mdl
MFCD03422203
分子量
188.131
InChiKey
XNQGDQMMYURPJK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    121-125°C
  • 沸点:
    298.0±25.0 °C(Predicted)
  • 密度:
    1.414±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2918990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:e402d5a35e0db696a9d6da24c68f14df
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: (2,4-Difluorophenoxy)acetic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: (2,4-Difluorophenoxy)acetic acid
CAS number: 399-44-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6F2O3
Molecular weight: 188.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2,4-二氟苯氧基)乙酸氯化亚砜 作用下, 以90%的产率得到2-(2,4-二氟苯氧基)乙酰氯化物
    参考文献:
    名称:
    含氟O,O-二烷基苯氧基乙酰氧基烷基膦酸酯的合成及除草活性
    摘要:
    设计并合成了一系列带有氟的取代苯氧基乙酰氧基烷基膦酸酯。通过元素分析,IR,1 H NMR和MS鉴定了所有新化合物,并以1.5 kg / ha的速率测试了温室中的除草活性。初步生物测定的结果表明,引入核心结构的氟部分可以帮助提高除草活性,苯环中带有3-三氟甲基的化合物表现出更高的抑制活性。
    DOI:
    10.1016/j.jfluchem.2005.11.013
  • 作为产物:
    描述:
    2-(2,4-二氟苯氧基)乙酸乙酯 在 sodium hydroxide 、 盐酸 作用下, 生成 (2,4-二氟苯氧基)乙酸
    参考文献:
    名称:
    1-(取代的苯氧基乙酰氧基)-1-(吡啶-2-基或噻吩-2-基)甲基膦酸酯的合成及生物活性
    摘要:
    一系列新颖的O,O-二甲基1-(取代的苯氧基乙酰氧基)-1-(吡啶-2-基或噻吩-2-基)甲基膦酸酯6a,6b,6c,6d,6e,6f,6g,6h,6i,合成了6j,6k,6l,6m,6n和7a,7b,7c,7d。其结构已通过IR确认11 H NMR,质谱和元素分析。初步生物测定的结果表明,某些标题化合物具有中等至良好的除草和杀真菌活性。例如,标题化合物6a,6c,6l,6m和7d在1500 g ai / ha的剂量下对大多数受试植物具有90-100%的抑制作用,而标题化合物6b,6g,6h和6n具有抑制作用针对92-100%抑制尖镰孢,Phyricularia菌,葡萄孢属cinereapers,玉蜀黍赤霉,浓度为50 mg / L的核盘菌菌核病菌(Sclerotinia sclerotiorum)和锥尾核孢菌(Cercospora beticola)。
    DOI:
    10.1002/jhet.1944
点击查看最新优质反应信息

文献信息

  • [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
    申请人:CALICO LIFE SCIENCES
    公开号:WO2017193034A1
    公开(公告)日:2017-11-09
    Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    本文提供了用于调节综合应激反应(ISR)并治疗相关疾病、疾病和症状的化合物、组合物和方法。
  • [EN] PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PDE9 INHIBITORS<br/>[FR] UTILISATION DE DÉRIVÉS DE PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE COMME INHIBITEURS DE PDE9
    申请人:CELON PHARMA SA
    公开号:WO2014016789A1
    公开(公告)日:2014-01-30
    A compound of the general formula (I) wherein R1 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, CN, -O-C1-C3-alkyl, fluorinated -O-C1-C3-alkyl, -(CH2)mOH and 5-membered heterocyclic group with 1 or 2 heteroatoms selected from N, O and S; and 6- or 10-membered heteroaryl with 1 to 3 heteroatoms selected from O, N and S; R2 and R3 independently of each other represent H atom or straight or branched C1-C3 alkyl; R4 is selected from the group consisting of 4- to 6- membered cycloalkyl, wherein one of carbon atoms can be replaced by O atom, and which is unsubstituted or substituted with one or two halogen atoms,and straight or branched C1-C4 alkyl; Q represents a bond or C1-C3-alkylene, which can be optionally substituted by one to three C1-C3-alkyls; X is selected from the group consisting of O, NR5, and S(O)p; R5 represents H atom or C1-C3alkyl; m is 1, 2 or 3; p is 0, 1 or 2; and salts thereof, for use as a medicament, in particular for treating cognitive function disorders and neurodegenerative diseases.
    通用式(I)的化合物,其中R1选自苯基未取代或取代的基团,所取代基团可为1至3个取自F、Cl、Br、I、CN、-O-C1-C3-烷基、氟代-O-C1-C3-烷基、-(CH2)mOH和含有1或2个取自N、O和S的杂原子的5元杂环基;以及含有1至3个取自O、N和S的杂原子的6-或10-元杂芳基;R2和R3彼此独立地代表H原子或直链或支链的C1-C3烷基;R4选自4-至6-环脂肪族基团,其中一个碳原子可被氧原子取代,未取代或取代有一或两个卤素原子,以及直链或支链的C1-C4烷基;Q代表键或C1-C3-亚烷基,可选择性地被1至3个C1-C3-烷基取代;X选自O、NR5和S(O)p的基团;R5代表H原子或C1-C3烷基;m为1、2或3;p为0、1或2;以及其盐,用作药物,特别用于治疗认知功能障碍和神经退行性疾病。
  • [EN] TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES<br/>[FR] DERIVES DE TETRAHYDRO-NAPHTHALENE ET D'UREE
    申请人:BAYER HEALTHCARE AG
    公开号:WO2005040100A1
    公开(公告)日:2005-05-06
    This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). BHC 03 2 001-Foreign-Countries - 66 - BHC 03 2 001-Foreign-Countries - 65 -
    这项发明涉及四氢萘和脲衍生物及其盐,这些物质可作为药物制剂的活性成分。本发明的四氢萘和脲衍生物具有辣椒素受体(VR1)拮抗活性,可用于预防和治疗与VR1活性相关的疾病,特别是用于治疗与VR1活性相关的泌尿系统疾病或紊乱,如膀胱过度活动(过度活跃膀胱)、尿失禁、神经源性膀胱过度活动(膀胱过度反射)、特发性膀胱过度活动(膀胱不稳定)、良性前列腺增生、下尿路症状;慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风,以及哮喘和慢性阻塞性肺病(COPD)等炎症性疾病。BHC 03 2 001-外国国家 - 66 - BHC 03 2 001-外国国家 - 65 -
  • [EN] TRICYCLIC PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PIPÉRIDINIQUES TRICYCLIQUES
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2015075023A1
    公开(公告)日:2015-05-28
    The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
    本发明涉及公式(I)的化合物,其中R、R1a、R1b、R2、R3和X如描述中所述,以及它们的制备方法,其药用盐,以及它们作为药物的用途,包括含有一个或多个公式(I)化合物的药物组合物,以及制备这种公式(I)化合物的方法,特别是它们作为TPH调节剂的用途。
  • [EN] COMPOUNDS, COMPOSITIONS AND METHODS<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS
    申请人:DENALI THERAPEUTICS INC
    公开号:WO2019046779A1
    公开(公告)日:2019-03-07
    The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    本公开涉及一般与真核起始因子2B调节剂相关的内容,或其药用盐、立体异构体、立体异构体混合物或前药,以及其制备和使用方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐